NCT01555879

Real-world Clinical Efficacy of Abatacept in the T3 Data Registry

Abatacept in T3: A Characterization of Abatacept's Efficacy and Outcomes From a Real-Word Clinical Practice Information Hub on Novel Patient Sub-Groups

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 200 (actual)
• Sponsor: Arthritis Northwest PLLC · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the effectiveness of Abatacept in real-world clinical practice. The main hypothesis to be examined in this study is, "Abatacept's effectiveness results in a single real-world clinic (n = 100) are reproducible at another site (n \~= 200)".

Detailed description

Two secondary hypotheses that will be tested are: * Abatacept aids in achieving low disease activity or clinical remission in patients of the following Rheumatoid Arthritis (RA) sub-groups: RF+/CCP+, RF+/CCP- RF-/CCP+ RF-/CCP-; first time on a bio-tech drug; having previously failed a biological drug; having interstitial lung disease; identified as disabled; twenty-eight individual joints identified as {swollen, painful, tender, deformed or having decreased range of motion}; on or not on oral DMARD; age; or gender. * A database with sufficient attributes exists from which a patient's efficacy on abatacept is accurately predictable.

Conditions

• Arthritis, Rheumatoid

Interventions

Type	Name	Description
DRUG	Abatacept	As prescribed by a doctor for patient medical care.

Timeline

• Start date: 2012-03-01
• Primary completion: 2016-11-01
• Completion: 2016-11-01
• First posted: 2012-03-16
• Last updated: 2017-11-06

Locations

1 site across 1 country: United States